Meridian Q3 Revenues Climb 5 Percent as MDx Products See Continuing Adoption
July 26, 2012
Meridian Q3 Revenues Climb 5 Percent as MDx Products See Continuing Adoption
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider - Dx Focus: Meridian's Illumigene Group A, B Strep Tests; Cynvenio Biosystems' LiquidBiopsy Service
March 21, 2013 / PCR Insider - Meridian Bioscience NAAT for Group A Strep Shines in Multicenter Clinical Study
March 7, 2013 / PCR Insider - Meridian Bioscience Reports 13 Percent Spike in Q1 Revenues Driven by Growth in Illumigene Products
January 24, 2013 / PCR Insider - Meridian Biosciences Views Universal Sample Prep Method as Enabler of Future MDx Tests
December 20, 2012 / PCR Insider